Eribulin Mesylate
Generic Name: eribulin mesylate
Brand Names:
Eribulin Mesylate
Eribulin mesylate is a prescription microtubule dynamics inhibitor, a synthetic analog of halichondrin B, available as 0.5 mg/mL injection for cancer treatment.
Overview
Eribulin mesylate is a prescription microtubule dynamics inhibitor, a synthetic analog of halichondrin B, available as 0.5 mg/mL injection for cancer treatment.
Uses
Indicated for metastatic breast cancer patients who previously received at least two chemotherapy regimens (including anthracycline and taxane), and unresectable or metastatic liposarcoma in patients with prior anthracycline treatment.
Dosage
Standard dose is 1.4 mg/m2 intravenously over 2-5 minutes on Days 1 and 8 of a 21-day cycle. Reduced doses recommended for hepatic or renal impairment.
Side Effects
Most common effects include neutropenia, anemia, fatigue, alopecia, peripheral neuropathy, nausea, and constipation. Serious reactions include febrile neutropenia and severe peripheral neuropathy.
Interactions
No clinically meaningful interactions with CYP3A4 inhibitors, inducers, or P-glycoprotein inhibitors.
Warnings
Monitor for neutropenia, peripheral neuropathy, embryo-fetal toxicity, and QT prolongation. Contraindicated in congenital long QT syndrome.
Pregnancy
Can cause fetal harm. Animal studies showed embryo-fetal toxicity at doses below recommended human dose.
Storage
Store at 20-25 degrees C. Do not freeze or refrigerate. Maintain in original cartons.
Frequently Asked Questions
What is Eribulin Mesylate used for?▼
Indicated for metastatic breast cancer patients who previously received at least two chemotherapy regimens (including anthracycline and taxane), and unresectable or metastatic liposarcoma in patients with prior anthracycline treatment.
What are the side effects of Eribulin Mesylate?▼
Most common effects include neutropenia, anemia, fatigue, alopecia, peripheral neuropathy, nausea, and constipation. Serious reactions include febrile neutropenia and severe peripheral neuropathy.
Can I take Eribulin Mesylate during pregnancy?▼
Can cause fetal harm. Animal studies showed embryo-fetal toxicity at doses below recommended human dose.
What are the important warnings for Eribulin Mesylate?▼
Monitor for neutropenia, peripheral neuropathy, embryo-fetal toxicity, and QT prolongation. Contraindicated in congenital long QT syndrome.
Related Medications
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.